blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4017531

EP4017531 - ANTI-CD19 ANTIBODIES AND USES THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  27.05.2022
Database last updated on 14.06.2024
FormerThe international publication has been made
Status updated on  26.02.2021
Most recent event   Tooltip29.11.2023Supplementary search reportpublished on 27.12.2023  [2023/52]
Applicant(s)For all designated states
Elpis Biopharmaceuticals
128 Spring Street, Building B
Lexington, Massachusetts 02421 / US
[2022/26]
Inventor(s)01 / CHEN, Yan
c/o Elpis Biopharmaceuticals,
128 Spring Street
Lexington, Massachusetts 02421 / US
02 / NGUYEN, Jenna
c/o Elpis Biopharmaceuticals,
128 Spring Street
Lexington, Massachusetts 02421 / US
03 / ZHAO, Kehao
c/o Elpis Biopharmaceuticals,
128 Spring Street
Lexington, Massachusetts 02421 / US
 [2022/26]
Representative(s)Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2022/26]Mössinger, Julia
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Application number, filing date20855355.219.08.2020
[2022/26]
WO2020US47035
Priority number, dateUS201962888724P19.08.2019         Original published format: US 201962888724 P
[2022/26]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021034952
Date:25.02.2021
Language:EN
[2021/08]
Type: A1 Application with search report 
No.:EP4017531
Date:29.06.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 25.02.2021 takes the place of the publication of the European patent application.
[2022/26]
Search report(s)International search report - published on:US25.02.2021
(Supplementary) European search report - dispatched on:EP28.11.2023
ClassificationIPC:C07K16/28, A61K39/00, A61P35/02
[2023/34]
CPC:
C07K16/2803 (EP,IL,KR,US); A61P35/00 (KR); A61P35/02 (EP);
C07K16/2809 (EP,IL,KR,US); G01N33/68 (KR); A61K2039/505 (KR);
C07K2317/21 (EP,IL,KR); C07K2317/24 (US); C07K2317/31 (EP,IL,KR,US);
C07K2317/565 (EP,IL,US); C07K2317/622 (EP,IL,KR,US); C07K2317/73 (EP);
C07K2317/76 (EP,IL,US); C07K2317/92 (EP,IL,KR,US); C07K2317/94 (EP,IL);
G01N2333/70596 (KR) (-)
Former IPC [2022/26]A61K39/00, C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/26]
TitleGerman:ANTI-CD-19-ANTIKÖRPER UND VERWENDUNGEN DAVON[2022/26]
English:ANTI-CD19 ANTIBODIES AND USES THEREOF[2022/26]
French:ANTICORPS ANTI-CD19 ET LEURS UTILISATIONS[2022/26]
Entry into regional phase11.03.2022National basic fee paid 
11.03.2022Search fee paid 
11.03.2022Designation fee(s) paid 
11.03.2022Examination fee paid 
Examination procedure11.03.2022Examination requested  [2022/26]
24.10.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
29.08.2022Renewal fee patent year 03
28.08.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]WO2015109131  (ZYMEWORKS INC [CA], et al) [I] 1-15* paragraphs [0007] , [0008] , [0 27] - [0032] - [0 49] , [0 50] , [0 55] , [0076] - [0080] - [0169] - [0172]; examples 1-10; claims 1, 23, 27-31, 35-39 *;
 [I]WO2017066136  (EUREKA THERAPEUTICS INC [US]) [I] 1-15 * figures 1, 2, 4-15; examples 1-6 *;
 [I]CN107793480  (SHANGHAI JIBEI BIOLOGICAL TECH CO LTD) [I] 1-15 * paragraphs [0010] - [0026] - [0034] - [0041] - [0051] - [0057] - [0059] - [0061] - [0076] - [0078]; examples 1-10; tables 4, 9-11 *;
 [I]WO2018108106  (CARSGEN THERAPEUTICS LTD [CN], et al) [I] 1-15 * paragraphs [0008] - [0030] - [0 67] - [0069] - [0098] , [0102] , [ 121] - [0137]; figures 5,9; examples 1-4 *;
 [I]WO2018161017  (OBSIDIAN THERAPEUTICS INC [US]) [I] 1-15 * paragraphs [0019] , [0020] , [0 46] , [0 47] , [ 164] , [ 193] - [0195] - [0208] - [0210] - [0354] - [0359]; examples 28-31 *
International search[X]US2014079691  (MCCONNELL AUDREY [US], et al) [X] 1-3 * entire document *;
 [A]US2016362472  (BITTER HANS [US], et al) [A] 1-3, 7, 8 * entire document *;
 [A]US2017088620  (NIOI PAUL [US], et al) [A] 1-3,7,8 * entire document *;
 [A]US2017152315  (HANSEN HANS J [US], et al) [A] 1-3, 7,8 * entire document *;
 [A]WO2018231759  (OBSIDIAN THERAPEUTICS INC [US]) [A] 1-3,7,8* entire document *;
 [A]WO2019075433  (ADIMAB LLC [US]) [A] 1-3,7,8 * entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.